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conducted in Spain and published between January, 2003 and April, 2009 were identi-
ﬁed. A combination of terms was applied to systematically review electronic and grey 
literature sources. Three Spanish journals were hand searched. Methodological quality 
was assessed applying the National Institute of Clinical Excellence (NICE) 10 criteria 
checklist and the Oxford Centre for Evidence Based Medicine (CEBM) recommenda-
tions for appraising economic evaluations. RESULTS: After applying the inclusion 
and exclusion criteria, a total of 48 papers and 1 Health Technologies Evaluation 
Agency (HTEAs) report were included. Key ﬁndings: 1) 69.5% of papers referred to 
therapeutic interventions; 30.4% to preventive strategies; 2) no assessments of diag-         
nostic procedures were identiﬁed; 3)10.4% dealt with medical devices; 4) Markov 
modelling was frequently applied (58.7%); 5) the NHS perspective was commonly 
adopted (56.5%); 6) costs and effects were usually discounted (71.7%); 7) probabi-
listic methods were reported in 36.4% papers; 8) in 91.9%, either the ICER or ICUR 
was stated; 9) effectiveness, costs and utility data came from Spanish sources in 15.2% 
publications; 10) 60.8% of studies were of 3b level of evidence mainly due to the 
diverse nature of the sources consulted to gather data, estimate utilities and design 
models; 11) 89% of authors compared their ﬁndings against an accepted threshold of 
a30,000 per QALY, but little attention was given to contrasting results or addressing 
other implementation issues; 12) 45.6% reported the source of funds. CONCLU-
SIONS: A small number of economic evaluations using QALYs was conducted. 
Diagnostic and preventive interventions as well as medical devices were scarcely con-    
sidered. Low evidence scores show that important methodological limitations remain 
unsolved to produce reliable estimates to guide the allocation of resources.
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OBJECTIVES: The dissemination of research ﬁndings begins with publication in peer-
reviewed journals and is continued by citation of the original study in other publica-
tions. The number of citations received by an article is one marker of study importance. 
We investigate whether the proliferation of the cost-effectiveness analysis (CEA) litera-
ture in recent years is matched by increased citations of study results. METHODS: 
We used the Tufts Medical Center registry of original CEAs published through 2006 
(www.cearegistry.org) (N  1394) to determine the journal name, and year of publica-
tion. We used the Science Citation Index Expanded (ISI Web of Knowledge, Thomson 
Reuters) to determine the extent to which each CEA has been cited in other publica-
tions. To control for different publication times, we calculated for each article the 
mean number of citations per year since study publication. RESULTS: Citation infor-
mation was available for 1,301 studies (94% of studies analyzed). The average (SD) 
number of citation counts per article was 26 (o 37) (range 0 to 391) and the average        
(SD) number of citations per year since article publication was 3.4 (o 3.9) (range 0 to    
34) and did not vary substantially by year of publication. The ten most cited CEAs 
by number of citations per year since publication were in high proﬁle medical journals 
(e.g., Lancet, New England Journal of Medicine) and were frequently co-authored by 
the most proliﬁc authors of cost-effectiveness research. These studies pertained mainly 
to coronary stents, implantable deﬁbrillators, HPV vaccination, screening and treat-
ment for HIV positive patients. CONCLUSIONS: CEAs are widely published and 
cited, but this phenomenon is not yet accompanied by an increase in citations. Further 
analyses is needed to analyze factors that may contribute to citation of CEAs, as well 
as measures to enhance better dissemination of this important body of research to 
researchers and decision-makers.
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OBJECTIVES: In recent years the literature regarding the cost-effectiveness of disease 
prevention and health promotion has grown exponentially. Aim of this study is an       
analysis of published economic evaluations on prevention: (i) how many economic 
evaluations are published (ii) what type of economic evaluations are published (cost-
effectiveness analyses, cost-utility analyses or cost beneﬁt analysis) (iii) which diseases     
or health problems (WHO-ICD-10 chapters) do economic evaluations of preventive 
interventions focus on (iv) how do those diseases or health problems relate to the 
burden of disease in the Netherlands? and (v) how cost-effective is prevention? 
METHODS: Economic evaluations on preventive measures were identiﬁed by search-
ing PubMed and Scopus. RESULTS: In the calendar year 2008, 232 economic evalu-
ations of preventive interventions are published. In 114 studies the QALY is used as 
outcome measure, in 46 LYS is used and 15 studies present both QALY and LYS. In 
38 studies the outcome measure is ‘cases prevented’. Most economic evaluations focus          
on the prevention of infectious diseases (73), cancers (49), cardiovascular diseases (23) 
and psychological- and behaviour disorders (16). Cardiovascular diseases are respon-
sible for the highest burden of disease (12.5%), followed by psychological- and 
behaviour disorders (11.5%). Of the cost-utility evaluations 84% show an incremental 
cost-effectiveness ratio (ICER) below a50,000 per QALY, of the cost-effectiveness 
evaluations almost 80% show an ICER below a50,000 per LYS. CONCLUSIONS: 
This study shows the disease clusters for which most preventive economic evaluations 
are published, and whether this corresponds with the diseases which cause much 
burden of disease and how cost-effective preventive interventions are. The conclusion        
of our study is that the published economic evaluations correspond rather well with 
the burden of disease in The Netherlands, with exception of infectious diseases and 
cancers. Finally, it appears that almost all published economic evaluations of preven-       
tive measures show favourable cost-effectiveness levels.
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OBJECTIVES: The last decade has witnessed a rapid expansion of biomedical knowl-
edge. Despite this, fashions in medical education over the same period have shifted 
away from factual (didactic) teaching and towards contextual, or problem-based,   
learning (PBL). This paradigm shift has been justiﬁed by studies showing that PBL 
improves reasoning and communication while being associated with few if any detect-
able knowledge deﬁcits. METHODS: A retrospective and comparative analytical 
approach was used. Data on ﬁnal Cardiopulmonary Resuscitation (CPR) exam grades, 
collected from PBL or traditionally trained students, and on teaching process, were            
obtained for a total of 2220 students. The data collection took place between 2003–
2008, in two major locations in Hungary and in Finland. The data analysis was done 
with Chi-square and ANOVA using SPSS14.0. PBL and traditional teaching methods          
were compared as well as the schools themselves. RESULTS: Students who received 
PBL training had better ﬁnal CPR exam grades than traditionally trained peers. T-test 
on means yielded signiﬁcant differences (t    3569; p   0.001) between PBL and con-    
ventional training favouring PBL taught students. The only signiﬁcant difference 
among universities was found for PBL training. There was no difference between the 
two universities in terms of ﬁnal CPR grades when traditional training was concerned.           
CONCLUSIONS: It is possible to indicate signiﬁcant differences in the perception of 
the development of problem solving skills between the two countries with the help of 
the khi square trial (khi2  17,974 f  3 p  0.01). The Finnish evaluated the efﬁciency 
of this method, in regard to developing problem solving skills, considerably higher 
than their Hungarian peers. One of the new and important messages of the study is           
to emphasise that the process of learning will not extend in one dimension for the 
whole life, and it will not conﬁned just for the formal school education.
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OBJECTIVES: Pharmacist’ role as patient counsellor/educator in the ambulatory set-
tings is essential for the rational use of drugs (RUD). The need for the qualiﬁed phar-
macy services enforce improvement of teaching methods in pharmacotherapy. 
Pharmacy students often face problems in implementing theorical pharmacotherapy 
knowledge to practice. Thus, novel methods (e.g. Groningen model) are developed for 
pharmacotherapy teaching. METHODS: A short course of “RUD Teaching” was 
conducted. Fifteen pharmacologists from 8 different pharmacy schools (of the total 
13) have attended the 4 day training course. On the ﬁrst day, attendants were subjected 
to a pretest which was based on the evaluation of their dispensing attitudes. For this 
purpose a simulated patient presented a prescription ordering a single drug for the 
treatment of his ailment. Attendants had a 3 day training similar to the Groningen 
model and ﬁnally they were subjected to a posttest. On the last day, trained attendants 
were expected to put their experience into practice with 12 pharmacy students. 
RESULTS: The results have shown that the average dispensing score of the 15 trainees 
(pharmacologists who received the training) which was 32/100 in the pretest, was 
increased to 72/100 at the end of the three days training. The questionnaire showed 
that all of the pharmacology lecturers agreed that the novel teaching method would 
improve the learning efﬁciency and communication skills of the student and change 
their dispensing attitude. On the otherhand 41.6% have stated that they believed the 
new teaching method would produce extra workload to their department. However, 
all of them have claimed that they would practice the new method in their depart-
ments. Also, the students have also stated that the course improved their dispensing 
skills. CONCLUSIONS: Although the course was conducted with a small group of 
trainees, results show that Groningen model can be adapted to RUD teaching in the 
Turkish pharmacy schools.
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OBJECTIVES: The aim of this study was to explore the views and perceptions of 
stakeholder’s about the current national health technology assessment process for new 
A250 Paris Abstracts
medical technologies and procedures conducted by the Medical Services Advisory 
Committee (MSAC). METHODS: Data collection was over a nine month period 
(August 2008 to April 2009). Twenty in-depth, semi-structured interviews were con-
ducted with four stakeholders groups: 1) MSAC committee members and evaluators; 
2) academic and health technology assessment experts; and 3) medical industry rep-
resentatives and (iv) specialists. Interviews were digitally recorded, transcribed verba-
tim and coded using a constant comparative method. RESULTS: The current MSAC 
decision-making process was described as generally fair and transparent. However 
stakeholder’s perceived that the burden of proof does vary from the evaluation of 
pharmaceuticals where “it’s largely resting on the sponsor”. It is perceived that the 
effectiveness of pharmaceuticals per se can be identiﬁed but that of medical devices 
and techniques has to be placed within the context of the specialist providing the 
service and setting. The MSAC process is described as more ﬂexible, “intuitive” and 
“idiosyncratic” due to the nature of the technologies being appraised (diagnostics, 
devices, procedures) and the different types of applicants. Unlike pharmaceuticals 
these technologies are more likely to be introduced and diffused in the Australian 
health care system without being evaluated by MSAC. CONCLUSIONS: The results 
of this study suggest that stakeholder’s perceived that the current process for evaluat-
ing non pharmaceutical technologies differs signiﬁcantly to that of pharmaceuticals. 
This was thought to be partially as a result of the intrinsic differences in the items 
under evaluation and partially due to the different institutional arrangements under 
which the evaluations take place. While differences in assessment for the former reason 
are generally justiﬁed, differences stemming from the latter may require consideration 
of what constitutes best practice, and possible amendment of the process.
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OBJECTIVES: HTA inSite is an on-line, subscription-based database of all NICE 
Technology Appraisals (TAs). It includes information relating to submitted evidence, 
appraisal process and ﬁnal decision and enables assessment of associated trends. 
METHODS: An academic steering group designed and agreed the data extraction 
protocol. A team of reviewers conducted the initial data extraction, which was vali-
dated by a second reviewer. Historical extraction is complete, with on-going TAs 
extracted on a monthly basis. RESULTS: A total of 161 TAs have been extracted to 
date, 4 of which were terminated, resulting in 157 complete TAs relating to 300 
technologies. Of these, 52% were awarded a restricted decision, 33% were fully rec-
ommended and 15% rejected. Of the three most commonly appraised disease areas 
(cancer, cardiovascular (CVS), central nervous system (CNS)); CVS technologies were 
least commonly rejected by NICE (3% vs. 17% for both cancer and CNS). Of the 
four most commonly used assessment groups (Shefﬁeld, York, Southampton and Bir-
mingham); technologies assessed by Shefﬁeld were most commonly rejected (28%) 
and those by York were least commonly rejected (3%). Technologies supported by a 
patient submission were less commonly rejected than those without (14% vs. 33%). 
A total of 30 TAs (19%) resulted in an appeal and in 5 (17%) of these cases the appeal 
was upheld completely, with 3 (10%) being partially upheld. HTA inSite also allows 
detailed analysis of individual TAs and cross-comparison between TAs as well as 
identifying trends between submitted evidence (acquisition costs, budget impact, cost-
effectiveness and clinical effectiveness) and ﬁnal outcome. These additional analyses 
will be further explored in the podium presentation. CONCLUSIONS: HTA inSite is 
a useful tool for anyone interested in understanding the relationship between submit-
ted evidence and ultimate NICE decision. The HTA inSite format may be useful for 
other HTA bodies, depending on the public availability of relevant information.
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OBJECTIVES: To compare HTA recommendations of Agency for Health Technology 
Assessment (AHTAPoL) in Poland with HTA recommendations of the Scottish Medi-
cines Consortium (SMC) by drug technology submitted to both Agencies for the same 
indication. METHODS: From 66 submissions, appraised by AHTAPol in the period 
January 1–December 31 2008, only drug technologies submitted to SMC for the same 
indication, were selected. Where there was more than one submission to a single 
Agency for the same indication, the most recent outcome was included. Appraisals 
were grouped into positive and negative recommendations. The clinical and non-
 clinical reasons for rejection of use were studied. The positive recommendations were 
divided into guidance with major, minor and without restrictions. RESULTS: Forty-
eight drug technologies were appraised by both Agencies. Similar recommendations 
were issued in 31 cases. A contradictory guidance was given at 17 occasions. Negative 
recommendations constituted 40% and 25% of all HTA appraisals issued by AHTAPol 
and SMC respectively. While clinical reasons prevailed in Poland (14 of 19 cases), 
poor economic data was the most often stated reason for negative guidance in Scotland 
(7 of 12 cases). Positive recommendations constituted 60% and 75% of all HTA 
appraisals issued by AHTAPol and SMC respectively. Major restrictions prevailed in 
both countries: 22 of 29 and 23 of 36 in Poland and Scotland respectively. AHTAPol 
issued 6 recommendations with minor restrictions. There were no such cases in Scot-
land. At the same time, SMC issued 13 positive recommendations without restrictions. 
AHTAPol generated only one such guidance. CONCLUSIONS: The positive HTA 
recommendations were more common in Scotland than in Poland in the group of drug 
technologies submitted to both Agencies for the same indication. While a clinical 
aspect was the most common reason for rejection in Poland, SMC pointed out mainly 
economic issues in their negative recommendations.
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OBJECTIVES: The National Centre for Pharmacoeconomics (NCPE) appraises the 
cost-effectiveness of new and existing technologies (medicines, diagnostics and devices) 
which may entail a high budget impact to the health system, in response to requests 
from the Health Service Executive (HSE). In the case of new medicines, assessments 
may be conducted prior to reimbursement application but must be completed within 
90 days. We describe the pharmacoeconomic evaluation process in Ireland and provide 
examples of recent appraisals and the subsequent impact on pricing and reimburse-
ment decisions. METHODS: The pharmacoeconomic appraisals conducted by the 
NCPE between September 2006 and May 2009 were reviewed. The NCPE recom-
mendations and subsequent reimbursement decisions by the HSE were recorded. The 
duration of the pharmacoeconomic process and the time from marketing authorisation 
to reimbursement was estimated. The budget impact assessments from the pharma-
ceutical companies were reviewed and compared for consistency. RESULTS: The 
NCPE conducted fourteen single technology appraisals during the study period. 
There is only one example of an existing medicine where cost-effectiveness data was 
requested to ensure continued reimbursement. All other evaluations were for newly 
licensed medicines. Eight of the medicines assessed were either recommended as a 
cost-effective use of resources or recommended with certain restrictions, and were 
funded by the HSE. Of the six medicines that were not considered cost-effective, two 
were reimbursed after a price reduction was negotiated, two were not reimbursed 
and the decision for the remaining two medicines is pending. The average duration of 
the pharmacoeconomic process was 2.7 months. The average time from marketing 
authorisation to reimbursement was 7 months. The review of budget impact assess-
ments highlighted a high degree of variability between submissions. CONCLUSIONS: 
The ﬁndings of this review demonstrate the efﬁciency of the pharmacoeconomic 
process and the acceptance of the NCPE recommendations by the HSE for pricing and 
reimbursement decisions.
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OBJECTIVES: Our objective was to assess whether 15 Key Principles, previously 
proposed by our group—the International Working Group for HTA Advancement—
could be applied to health technology assessment (HTA) programs in different jurisdic-
tions and across a range of organizations and perspectives. METHODS: We 
investigated the extent to which 14 HTA organizations around the world implicitly 
support and implement the Key Principles. By “support,” we meant that the organiza-
tion backs the principle in written guidelines or other form, regardless of whether they 
actually follow it. By “implemented,” we meant that published reports and decisions 
based on reports were consistent with the principles. The HTA organizations were 
chosen to include examples of both established and emerging entities with different 
roles and objectives. They include HTA organizations in Australia (PBAC), Brazil 
(ANVISA), Canada (CADTH), Germany (DAHTA@DIMDI, IQWiG), Korea (HIRA), 
Sweden (TLV, SBU), Taiwan (CDE), the UK (NICE), and United States (Blue Cross/
Blue Shield, CMS, DERP, Wellpoint). RESULTS: There is considerable variation in 
practices across the HTA organizations. Many of the organizations support and imple-
ment certain principles, such as being explicit about their HTA goals and scope; con-
sidering a wide range of evidence and outcomes; and seeking all available data. Other 
principles, such as taking a full societal perspective; having a clear system for setting 
priorities; explicitly characterizing uncertainty surrounding estimates; monitoring the 
implementation of HTA ﬁndings; and considering the generalizability and transfer-
ability of results receive much less backing. There is also variation in the degree to 
which organizations incorporate appropriate methods for assessing costs and beneﬁts. 
CONCLUSIONS: There is considerable room for improvement for HTA organiza-
tions to adopt principles identiﬁed to reﬂect good HTA practices. A broader discussion 
is needed on principles that do not receive widespread support and implementation.
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OBJECTIVES: Wireless telecommunication technology is commonplace in today’s 
life including health care environment. Critical care medical equipment such as      
